Breast cancer

This trial tests a planned sequence of treatments for people with advanced or metastatic HER2-positive and hormone receptor-positive breast cancer. Participants first receive T-DXd (Enhertu) plus pertuzumab, then switch to a maintenance combination of palbociclib, endocrine thera…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This phase 3 trial tests whether adding the targeted drug inavolisib to standard maintenance therapy (Phesgo) can delay cancer growth in people with a specific genetic mutation (PIK3CA) in HER2-positive advanced breast cancer. About 230 participants who have already completed ini…

This study is testing a program called WeCan-Rural for breast cancer survivors living in rural, underserved areas. The program includes 12 weekly video sessions to help manage symptoms like pain and fatigue, and build healthy habits around eating, exercise, and weight. The goal i…

This study tests a new drug called BGB-43395 combined with letrozole against standard CDK4/6 inhibitor drugs (abemaciclib, palbociclib, or ribociclib) plus letrozole for people with advanced or metastatic HR+/HER2- breast cancer who have not had prior treatment for advanced disea…

Researchers are testing a drug called ARX788 in people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The study gives ARX788 as an intravenous infusion every six weeks. The main goal is to see how many participants see their tumors shrink or dis…

This phase 3 trial is testing whether adding the targeted drug ribociclib to standard hormone therapy can help prevent invasive breast cancer from returning in people with HR+ HER2- early breast cancer. About 1,400 participants will receive the combination for up to 3 years. The …

This study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

Researchers are testing whether adding anlotinib to vinorelbine helps control HER2-negative advanced breast cancer that has worsened after standard chemotherapy. The trial enrolls women aged 18 and older who have had up to four prior treatment lines. Participants receive either t…

This early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …

This phase 2 trial is testing the safety of abemaciclib (Verzenio) combined with hormone therapy in people aged 70 and older with hormone receptor-positive metastatic breast cancer that has worsened after prior treatment with a similar drug. The study will enroll 43 participants …

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This early-phase trial tests the safety and best dose of a new drug combination—pidnarulex plus trastuzumab deruxtecan—in people with advanced breast cancer and other solid tumors that have the HER2 protein. The study enrolls 36 adults whose cancer has spread or cannot be surgica…

This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sar…

This trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This phase 2 trial is testing whether turkey tail mushroom extract can slow or shrink estrogen receptor-positive, HER2-negative breast cancer in post-menopausal women. Forty participants will take the supplement between diagnosis and surgery, and researchers will measure changes …

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…

Researchers are testing an experimental oral drug called XNW29016 in adults with advanced solid tumors that have not responded to standard treatment. The trial has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look at early signs of activity…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This study tests an experimental drug called JAB-23E73, taken as a pill, in adults with advanced solid tumors that have a KRAS alteration. The trial has three parts: first finding a safe dose, then optimizing it, and finally checking if the drug shrinks tumors in certain cancers …

This study compares two treatments for people with high-stage, estrogen-positive, HER2-negative breast cancer that has a low genetic risk of returning. One group gets standard hormone therapy plus a targeted pill (ribociclib), while the other gets chemotherapy first, then the sam…

This study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, …

This trial explores whether people with early-stage triple-negative breast cancer and high levels of tumor-infiltrating lymphocytes (TILs) can safely skip a class of chemotherapy drugs called anthracyclines, which are effective but can harm the heart. Participants receive 12 week…

Researchers are testing whether combining two oral drugs, SHR2554 and HRS-8080, can help people with advanced breast cancer. The trial enrolls about 30 adults with measurable tumors who have adequate organ function. Doctors give both drugs together and track how many patients see…

This phase III trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can prevent breast cancer from returning in people with a specific high-risk type of hormone receptor-positive, HER2-negative breast cancer. About 3,680 participants with sta…

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of breast cancer (…

This study tests whether a combination of three drugs (anastrozole, fulvestrant, and abemaciclib) can shrink or control tumors in people with a common type of advanced breast cancer (hormone receptor positive, HER2-negative). About 20 participants whose cancer has spread or retur…

This study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This phase II trial is testing an experimental drug called SMP-656 in people with HER2-positive breast cancer that has spread or cannot be removed and has worsened after prior treatment with a specific type of antibody-drug conjugate. The study aims to see if SMP-656 can shrink t…

This phase 2 trial is testing whether combining an experimental immunotherapy (MK-2010) with an antibody-drug conjugate (sacituzumab tirumotecan) can help people with advanced solid tumors. The goal is to see if the combination is safe and can shrink or eliminate tumors. Particip…

Researchers are running a Phase I trial of BA1203, an experimental drug given intravenously every two weeks, in adults with advanced solid tumors that have worsened after standard treatments. The study aims to find out whether BA1203 is safe and tolerable, how the body processes …

This early-phase trial tests an experimental drug called BSI-082, alone or combined with a standard cancer drug (T-DXd), in 57 adults with advanced or metastatic solid tumors that have not responded to other treatments. The study has two parts: first, finding the safest dose of B…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.

This early study tests an experimental drug called XB010, alone or combined with the immunotherapy pembrolizumab, in people with advanced solid tumors (like lung, breast, or head and neck cancers) that have stopped responding to other treatments. The main goals are to find a safe…

This phase 2 trial is testing whether a combination of lenvatinib (a targeted drug) and a PD-1 inhibitor (immunotherapy) can shrink or stop advanced solid tumors that have a specific genetic change called 11q13 amplification. About 60 adults with various cancers like esophageal, …

This study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…

Researchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…

This phase 2 trial tests an experimental drug called YL202 in people with advanced or metastatic breast cancer that has not responded to other treatments. The study includes patients with triple-negative breast cancer (TNBC) or hormone receptor-positive, HER2-zero or HER2-low tum…

This study will test a device called LumiSystem that helps surgeons see if any cancer cells are left behind during breast cancer surgery. About 1500 women having a lumpectomy will be included. The goal is to see if using this imaging tool reduces the number of patients who need a…

This phase 2 trial is testing whether adding a special type of radiation called adaptive pulse radiotherapy to standard immunotherapy can help treat advanced solid tumors. The study will enroll 35 people who are already receiving or planning to receive immune checkpoint inhibitor…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body to better fight the cancer. Th…

This early-stage trial tests the safety and best dose of two oral drugs, ZEN003694 and binimetinib, taken together. It is for people with advanced solid tumors that have RAS pathway changes or triple-negative breast cancer that has spread or cannot be removed. The goal is to find…

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This phase II trial is testing whether combining an experimental antibody called SSGJ-612 with a targeted chemotherapy (an antibody-drug conjugate) can shrink tumors in people with hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer. The study enrolls ab…

This phase 3 trial is testing whether adding a targeted therapy called Sacituzumab tirumotecan (Sac-TMT) to standard chemotherapy and immunotherapy (pembrolizumab) can better eliminate cancer before surgery in people with high-risk, early-stage triple-negative or hormone-receptor…

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), given alone or with pembrolizumab, helps people with advanced triple-negative breast cancer live longer or keep their cancer from growing. About 1,000 adults whose cancer has spread and who have not had prior…

Researchers are running a first-in-human Phase I trial of AK157D1, an experimental drug given by intravenous infusion, in adults with advanced solid tumors that have worsened after standard treatment or have no standard options left. The study aims to find out whether the drug is…

This phase 3 trial tests whether a new drug (MK-2870), alone or with another drug (pembrolizumab), works better than standard treatments for people with a common type of advanced breast cancer (HR+/HER2-). About 1,200 participants whose cancer has worsened after hormone therapy w…

This study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 par…

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

Researchers are running a first-in-human Phase 1 trial of BA1302, an intravenous drug, in adults with advanced solid tumors including melanoma, breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma. The trial has two parts: a dose-escalation phase to find a saf…

This study is testing a 5-session radiation treatment (stereotactic body radiotherapy) for people with early-stage breast cancer who have already had a lumpectomy. The goal is to see if this shorter course is safe and has fewer side effects than standard longer radiation. About 4…

Researchers are running a first-in-human Phase 1 trial of BA1106, an experimental intravenous drug, in adults with advanced solid tumors that have worsened after standard treatments. The main goal is to check safety and tolerability, and to see how the body processes the drug. Pa…

This Phase 1 trial is testing ZOLADEX (goserelin), a hormone-blocking implant, in 88 premenopausal women with HR+/HER2- advanced breast cancer. The goal is to see if it can temporarily shut down ovarian function, which may help control the cancer. Participants receive two injecti…

Researchers are testing an engineered interleukin-2 drug called MDNA11 in adults with advanced solid tumors. The trial gives MDNA11 alone or with pembrolizumab, an immune checkpoint inhibitor, to see which doses are safe and how the body processes the drug. It also looks for earl…

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This study tests whether a combination of two drugs (sacituzumab govitecan and pembrolizumab) given after surgery works better than standard treatments to prevent breast cancer from coming back. It is for people with triple negative breast cancer who still have cancer cells in th…

This study tests a new drug called HY07121 in 258 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV infusion. The main goals are to check safety, find the right dose, and see if it can shrink tumors. This is an early-stage t…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

Researchers are running a first-in-human Phase 1 trial of BA1301, an experimental drug given intravenously every three weeks, in adults with advanced solid tumors that cannot be removed by surgery. The trial enrolls about 70 people aged 18 to 75 whose cancer has progressed after …

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This study is testing whether a generic version of the chemotherapy drug paclitaxel albumin-bound works the same as the brand-name version in people with breast cancer. The trial involves 24 participants who will receive both versions at different times to compare how the drug be…

Researchers are testing whether combining brain radiation with trastuzumab rezetecan works better than the drug alone in women with HER2-positive advanced breast cancer that has spread to the brain. About 224 participants will be randomly assigned to receive either the drug plus …

This study is testing whether women with early-stage breast cancer that has not spread to lymph nodes can safely skip radiation therapy after a lumpectomy, if their tumor completely disappeared with chemotherapy. The trial will enroll 352 women and follow them for cancer recurren…

This study tests a new drug, zunsemetinib, combined with standard chemotherapy (capecitabine) in people with a common type of advanced breast cancer (HR+/HER2-) that has spread to the bones. The goal is to see if the combination is safe and can slow down the cancer or reduce bone…

This trial is testing an oral drug called elacestrant in Japanese patients with a specific type of advanced breast cancer (ER+/HER2-) that has a mutation in the ESR1 gene and has progressed after prior endocrine therapy including a CDK4/6 inhibitor. The study aims to see if elace…

This study tests whether adding a personalized vaccine (made from unique tumor proteins) to a combination of chemotherapy and two immunotherapy drugs can better control metastatic triple-negative breast cancer. About 70 participants will be randomly assigned to receive the vaccin…

This early-phase trial tests whether combining two oral drugs, neratinib and ruxolitinib, is safe and can shrink tumors in people with metastatic triple-negative breast cancer that has come back on the chest wall after chemotherapy. About 20 women will take the drugs daily, and d…

This phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (MK-2870) to the immunotherapy pembrolizumab can better prevent breast cancer from coming back in people with triple-negative breast cancer who still had tumor after initial treatment. About 1,5…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This expanded access program provides giredestrant, a daily oral drug, to people with ER-positive, HER2-negative breast cancer (early or advanced) who have limited treatment options. The goal is to offer early access before the drug is commercially available in the US. Participan…

Researchers are testing whether combining utidelone, an intravenous drug, with capecitabine, an oral drug, can shrink brain metastases from triple-negative advanced breast cancer. The trial enrolls 48 adults with confirmed invasive breast cancer and metastatic disease. The main g…

This early-stage study is testing a new drug called AT03-65 in 83 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose, while also looking for early signs that the drug might shrink tumors. Part…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

This early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364…

This early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …

This phase III trial is for people with HER2-positive stage IV breast cancer that has spread to a limited number of spots (oligometastatic). It tests whether adding surgery and focused radiation to standard drug therapy helps them live longer or delays cancer growth compared to d…

This study tests whether giving radiation early to spine tumors that are not yet painful can prevent serious problems like fractures or spinal cord compression. About 74 adults with cancer that has spread to the spine will receive radiation before symptoms get worse. The goal is …

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This study tests a new daily pill, camizestrant, against standard hormone therapies to see if it better prevents breast cancer from returning in people with ER+/HER2- early breast cancer who are at intermediate or high risk. About 4,300 participants who have already completed ini…

This study tests a new drug called MHB046C in 200 people with advanced solid tumors that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug intravenously every three weeks.

This phase 3 trial is testing a daily pill called giredestrant in 300 people with ER+/HER2- early breast cancer who had to stop standard aromatase inhibitors due to side effects. The study will track how well patients stick with the treatment, their quality of life, and any side …

This study tests a new drug called GVV858, alone or with hormone therapy, in people with advanced hormone receptor-positive, HER2-negative breast cancer and other solid tumors. The goal is to find the safest dose and see how well it works. About 205 adults whose cancer has progre…

Researchers are testing an experimental antibody injection called MHB118C in adults with advanced solid tumors that have not responded to standard treatments. The trial aims to find out whether the drug is safe, what side effects it causes, and what dose people can tolerate. Part…

This early-phase study tests a new drug called IEV407, alone or with hormone therapy, in people with advanced HR+/HER2- breast cancer that has stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 194 participants will take p…

This study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…

This study tests whether a blood test measuring thymidine kinase activity (TKa) can help doctors decide early if a patient's breast cancer treatment is working. Patients with HR+ HER2- metastatic breast cancer start standard therapy with a CDK4/6 inhibitor and endocrine therapy. …

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This study tests whether a new quarterly injection of letrozole delivers the same amount of medicine into the body as the standard daily pill. It involves 120 postmenopausal women who have already completed at least 4-5 years of hormone therapy for early breast cancer. The goal i…

This phase II trial is testing whether combining two drugs—trastuzumab deruxtecan (Enhertu) and durvalumab—given before surgery can eliminate cancer in people with stage III inflammatory breast cancer that has HER2 protein. The study will enroll 63 participants and measure how ma…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This study tests two experimental drugs, MHB036C and MHB039A, given together to people with advanced breast cancer or other advanced solid tumors that have spread. The goal is to see if the combination is safe and can shrink tumors. About 210 adults aged 18 to 75 with measurable …

Researchers at the Jules Bordet Institute are studying whether two existing drugs, the painkiller ketorolac and the nerve drug pregabalin, can reduce inflammation and nerve signals around breast cancer surgery. The trial enrolls 112 women with early-stage, estrogen-receptor-posit…

This early-stage study tests a new drug, APX-343A, alone or with another cancer drug (pembrolizumab) in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Ab…

This early-phase trial tests two experimental drugs, MHB088C and MHB039A, given together by IV to people with advanced solid tumors that no longer respond to standard treatments. The study has two stages: first, finding the safest dose, then checking if the combination can shrink…

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This study tests a combination of two drugs, elacestrant and abemaciclib, in people with a specific type of breast cancer (ER-positive, HER2-negative) that has spread to the brain. The goal is to see if the combination can shrink or control brain tumors. The trial involves about …

This study tests the drug ponatinib in children aged 1 to 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the drug can shrink tumors or improve blood counts. About 70 chil…

This early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …

This Phase 3 study tests whether adding the experimental drug gedatolisib to standard hormone therapy and palbociclib can delay cancer growth better than the current standard treatment (hormone therapy plus ribociclib) in people with HR-positive, HER2-negative advanced breast can…

This study tests an experimental drug called TRK-950 in people with advanced solid tumors or melanoma that has not responded to standard treatments. The first parts check safety and side effects when given alone or with another cancer drug (nivolumab). The final part looks at whe…

This study tests histotripsy, a non-invasive treatment that uses focused ultrasound to destroy liver tumors without needles or surgery. It involves 40 adults with liver cancer who cannot have surgery or other standard treatments. The goal is to see if it is safe and effective at …

This early-stage trial tests a new drug called CT-202 in people with advanced triple-negative breast cancer, colorectal cancer, or bladder cancer that has come back or spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells that have a pro…

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

Researchers are testing a focused, dose-escalated radiotherapy technique called DE-iPTV in adults with breast cancer that has spread to the brain. The trial enrolls people who would normally receive whole-brain radiotherapy. Participants receive five radiotherapy doses and comple…

Researchers are testing whether a specialized radiation technique called lattice radiotherapy, combined with PD-1/PD-L1 inhibitor drugs, can safely shrink large tumors in people with advanced solid cancers. The trial enrolls adults whose cancer has progressed after standard treat…

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and CDK4/6 inhibitors can better control advanced HR+ HER2- breast cancer with a PIK3CA mutation. About 920 adults who have not had prior treatment for advanced disease will participate. The goal i…

This early-phase study is testing an experimental drug called CLR 125 in 60 people with advanced triple-negative breast cancer that has not responded to prior treatments. The main goals are to find the safest and most effective dose and to understand what side effects occur. Part…

This study tests a new oral drug called imlunestrant in premenopausal women with estrogen receptor-positive, HER2-negative breast cancer. Some participants will also receive a drug to suppress ovarian function. The effects on tumor cells and ovaries will be compared with those of…

This study tests a new drug, patritumab deruxtecan, against standard chemotherapy or another drug for people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if the new drug helps people live longer or keeps the cancer from growing. About 1000 particip…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This study tests whether precise radiation (SBRT) can treat a few growing tumors in patients with ER+ breast cancer that has spread, allowing them to continue their current medication longer. About 18 adults with limited disease progression will receive SBRT and be monitored. The…

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This study tests whether two drugs, pembrolizumab and lenvatinib, can shrink brain tumors in people with breast cancer, lung cancer, or other solid tumors that have spread to the brain. About 87 participants will receive the combination therapy. The goal is to see how well the tr…

This study compares standard surgery alone versus a short course of radiotherapy followed by surgery for women with ductal carcinoma in situ (DCIS), a very early form of breast cancer. The goal is to see if pre-surgery radiation can completely eliminate the cancer cells in the re…

This study is for people with breast cancer that has spread to only a few spots in the body (oligometastasis). It tests whether adding focused treatments like radiation or surgery to the cancer spots, along with standard drug therapy, can help people live longer. About 340 partic…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This Phase 3 trial tests whether elacestrant, a new hormone therapy, can prevent distant metastasis better than standard hormone therapies in 220 patients with ER+/HER2- breast cancer whose blood tests show signs of cancer DNA (ctDNA) but no visible spread. Participants are rando…

This early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to standard treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it …

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has a PIK3CA gene change and has stopped responding to hormone therapy. About 500 participants in China will receive inavolisib as part of their regular care. Rese…

This phase 2 trial is testing the drug sacituzumab govitecan (Trodelvy) as a first treatment for people with advanced triple-negative breast cancer who haven't had prior therapy for advanced disease. Researchers want to see if the drug can shrink tumors or slow the cancer's growt…

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…

This study is testing several different drug combinations in people with advanced ER-positive breast cancer that has stopped responding to prior treatments. The trial is designed like an 'umbrella,' allowing new drug combos to be added as they become available. About 316 particip…

This study tests a drug called patritumab deruxtecan in people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors and how safe it is. About 81 adults will take part. This is not a cure, but aims to co…

This study tests a new drug, RO7771950, designed to reach the brain, for people with HER2-positive breast cancer that has spread to the brain or other organs. About 650 participants will receive either the new drug or an existing drug (tucatinib), both combined with standard ther…

This phase 2 trial is testing whether adding a drug called inavolisib to two standard treatments (ribociclib and fulvestrant) can shrink tumors or slow cancer growth in people with advanced hormone-receptor-positive, HER2-negative breast cancer that has a specific genetic change …

This study tests whether adding the drug inavolisib to standard hormone therapy and a CDK4/6 inhibitor can help people with a specific type of advanced breast cancer (PIK3CA-mutated, HR+, HER2-). About 450 adults whose cancer has not been treated yet in the advanced setting will …

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This phase 3 trial tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with advanced triple-negative breast cancer (TNBC) live longer without their cancer growing. Participants have TNBC that cannot be treated with current PD(L)1 immunotherapie…

This study tests MK-5684, a drug that blocks the body from making steroid hormones, in people with breast, ovarian, or endometrial cancer. Researchers want to see if it helps patients live longer without their cancer growing compared to standard treatments. The trial is recruitin…

This study is for people with breast cancer who need a mastectomy (breast removal) followed by immediate breast reconstruction using their own tissue. It compares two ways of giving radiation before surgery: the standard longer course versus a shorter course with fewer, higher do…

This study tests whether the antiviral drug letermovir can prevent cytomegalovirus (CMV) infection in children and teens who have had a stem cell transplant. About 105 participants aged 2 to 17 will receive letermovir and be monitored for 14 weeks. The goal is to see if the drug …

This study tests two different doses of inavolisib combined with fulvestrant in people with a specific type of advanced breast cancer (PIK3CA-mutated, HR-positive, HER2-negative). About 80 participants whose cancer worsened after prior treatment will receive the drug combo. The g…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This study tests a new drug called GDC-4198, alone or combined with another drug (giredestrant), against a standard treatment (abemaciclib plus giredestrant) in people with advanced ER+/HER2- breast cancer that has worsened after prior CDK4/6 inhibitor therapy. The trial has two …

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase study is testing two drugs together — alpelisib and pembrolizumab — in people with metastatic breast cancer or melanoma that has spread to the brain or other organs. The main goal is to find a safe dose and see what side effects occur. Up to 50 adults whose cance…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This early-phase study tests a new drug called OP-3136 in people with advanced breast, lung, or prostate cancers that have not responded to other treatments. The drug works by blocking certain enzymes that help cancer cells grow. The study will first find a safe dose, then test i…

Researchers are testing an experimental oral drug called T-1301 in people with advanced solid tumors or lymphoma that have not responded to standard treatments. The Phase I trial aims to find the highest dose participants can tolerate and the dose best suited for later studies. A…

This early-phase trial tests a new drug called AVA6103 in 174 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, potentially killing cancer cells while r…

This study is testing a new robotic method for nipple-sparing mastectomy in people with breast cancer or a high risk of developing it. The goal is to see if the robotic approach is as safe and effective as standard surgery, while possibly improving nipple sensation and patient sa…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This study compares two drug combinations for people with a type of advanced breast cancer (HR+/HER2-) that has a specific genetic change (PIK3CA mutation) and has worsened after prior treatment. About 540 adults will receive either the experimental drug RLY-2608 plus fulvestrant…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This study tests a high dose of the chemotherapy drug methotrexate given through a vein in people with breast cancer that has spread to the lining of the brain. The goal is to see if it helps them live longer. The trial includes adults with triple-negative, HER2-positive, or horm…

This trial investigates whether women aged 60 and older with a very small, low-risk type of breast cancer can safely avoid hormone therapy after surgery. Participants will not receive standard drugs like tamoxifen or letrozole, and researchers will track cancer recurrence for up …

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

Researchers are testing an experimental intravenous drug called T-1201 in adults with advanced solid tumors that have not responded to standard therapy or have no standard treatment left. The main goals are to find the highest dose people can tolerate and the dose best suited for…

Doctors usually wait for biopsy results before giving radiation, but that wait can be long and painful for patients with advanced cancer. This trial tests whether giving palliative radiation first, before a biopsy confirms cancer, is safe and practical for a carefully selected gr…

This study gives people who are already benefiting from the cancer drugs encorafenib and/or binimetinib in earlier trials continued access to these medicines for up to 5 years. It includes safety monitoring and is open to about 46 participants whose doctors confirm they are still…

This study is testing a drug called Dato-DXd in 100 people with a type of advanced breast cancer (HR-positive, HER2 IHC 0) that has stopped responding to hormone therapy. Participants receive the drug by IV every 3 weeks. The goal is to see if it can slow cancer growth and to che…

This phase 3 trial is testing whether 6 months of HER2-targeted therapy (trastuzumab and pertuzumab) works as well as the standard 12 months for people with early-stage HER2+ breast cancer who had a complete response to initial chemotherapy. About 1,500 participants will be rando…

This study tests whether giving a precise, high-dose radiation treatment called SBRT to one growing tumor can help people with metastatic breast cancer keep their disease under control. Participants continue their usual drug therapy while receiving SBRT to a single site where can…

This study tests a new drug called HRS-8080 against standard treatments chosen by doctors for women with advanced breast cancer that has worsened after hormone therapy. About 240 women aged 18-75 will take part. The main goal is to see if HRS-8080 can delay cancer growth longer t…

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

Researchers are testing an experimental oral drug called GH56 in people with advanced solid tumors that have lost the MTAP gene. The trial enrolls adults and adolescents whose cancer has progressed after standard treatment or who have no standard options left. The study first fin…

This study tests a drug called alisertib combined with hormone therapy for people with a common type of advanced breast cancer (HR+, HER2-). The cancer has continued to grow despite at least two prior hormone treatments. The goal is to find the best dose of alisertib and see if t…

This study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …

This phase II trial is testing whether giving the hormone therapy drug goserelin (Zoladex) as a shot in the upper buttock works as well as the standard belly injection for suppressing ovarian function in premenopausal women with hormone-positive breast cancer. About 98 patients w…

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

Researchers are testing a new oral drug called HTL0039732 in people with advanced solid tumors that have not responded to standard treatments. The trial gives the drug alone and in combination with atezolizumab or other approved cancer therapies. The main goals are to find a safe…

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

This study tests whether adding zanidatamab to standard chemotherapy can completely eliminate cancer in people with early-stage HER2-positive breast cancer before they have surgery. About 125 participants with stage II or III disease will receive the combination, and doctors will…

This study tests an experimental drug, hetrombopag, to see if it can safely raise platelet counts in cancer patients whose platelets drop too low after chemotherapy. About 150 adults with solid tumors (like lung, breast, or colon cancer) will receive either the drug or a placebo …

This trial is studying a combination of two targeted drugs, patritumab deruxtecan and trastuzumab deruxtecan, for people with a specific type of advanced breast cancer that is hormone receptor positive and has low or ultra-low levels of a protein called HER2. The study aims to fi…

This study tested three flavors of Supportan® drink (Tropical Fruits, Cappuccino, and Pineapple-Coconut) in 123 cancer patients undergoing chemotherapy, radiotherapy, immunotherapy, or targeted therapy. Patients drank two bottles daily for four weeks alongside their normal diet. …

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the best dose and check if it is safe and shrinks tumors. All participants get the drug by injection, and the study invol…

This early-stage trial is testing an experimental drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study involves adults with locally advanced or metastatic head and neck tumors or other solid tumors. The main goals are to assess the…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This early-phase trial tests a new type of immune cell therapy for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own natural killer (NK) cells that have been genetically modified to produce IL-15, a protein that hel…

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

Researchers compare two types of breast-conserving surgery in women who have received chemotherapy before surgery for invasive breast cancer. One method uses an endoscope (a thin tube with a camera) to remove the tumor through a small hidden incision, while the other uses a tradi…

Researchers are observing whether injecting an engineered adenovirus called H101 directly into tumors, combined with immune checkpoint inhibitors, can shrink advanced breast cancer that has worsened after standard treatment. The study plans to enroll 10 to 15 adults with Stage IV…

This study tests a lower daily dose of the chemotherapy drug capecitabine in 40 patients aged 60 or older, or those who are frail, with advanced breast cancer. The goal is to see if this gentler dose can still shrink tumors while causing fewer side effects. Participants will take…

This study looks at how different group exercise programs affect fitness and body composition in women who have finished breast cancer treatment. About 15 women will try one of four supervised resistance training regimens. The goal is to see which approach best improves heart-lun…

This phase III trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy (PD-1 antibody), works better than standard chemotherapy plus immunotherapy for people with advanced triple-negative breast cancer that has a specific protein (PD-L1). The study inc…

This early-phase trial tests a new drug called ZEN003694 combined with immunotherapy (pembrolizumab) and chemotherapy (nab-paclitaxel) in 57 people with advanced triple-negative breast cancer. The goal is to find a safe dose and see if the combo can shrink tumors or slow the canc…

This early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This early-phase trial is testing whether a new drug called ZEN003694, when added to the chemotherapy capecitabine, is safe for people with advanced solid tumors that have spread or can't be removed by surgery. About 30 participants will receive the combination to find the best d…

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

Researchers are testing whether adding dalpiciclib to standard hormone therapy helps women with early-stage ER-positive, HER2-negative breast cancer that has not spread to lymph nodes but has other risk factors. The trial enrolls about 1,388 women aged 18 to 70 who have had surge…

This early-stage study tests a new drug, AUBE00, in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have a spec…

This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage triple-negative breast cancer (TNBC). TNBC is harder to treat than other breast cancers, and this combination aims to boost the im…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study compares a 3-week course of proton radiation to the standard 5-week course for women with breast cancer who need radiation to the breast or chest wall and nearby lymph nodes. The goal is to see if the shorter schedule causes fewer severe skin and tissue side effects wh…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This study tests proton radiation therapy for women with early-stage breast cancer. The goal is to see if targeting only the tumor area can keep cancer from coming back while causing fewer side effects. About 132 women aged 50 and older will take part. Researchers will track recu…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study tests two experimental drugs, camizestrant and atirmociclib, in 24 people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has worsened after prior treatment. The main goal is to check safety and how the body processes the drugs, with ea…

This early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …

This study tests whether a chemotherapy-free treatment using the targeted drug Dalpiciclib (a CDK4/6 inhibitor) plus hormone therapy works as well as standard chemotherapy for women with small, high-risk, hormone-receptor-positive breast cancer. About 2,288 participants will be r…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This Phase 3 study tests whether a new drug, inavolisib, combined with fulvestrant works better than the current standard alpelisib plus fulvestrant for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation). The trial enrolled …

This study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests whether active surveillance (close monitoring) combined with hormonal therapy can safely manage ductal carcinoma in situ (DCIS), a very early form of breast cancer. About 400 women with hormone-positive DCIS will receive either standard or investigational hormone…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

Researchers compare two adjuvant chemotherapy regimens in women with early-stage, high-risk ER+/HER2- breast cancer that has spread to four or more lymph nodes. One group receives docetaxel plus carboplatin (TCb), and the other receives epirubicin plus cyclophosphamide followed b…

This early-phase trial is testing a new drug called BHV-1510, either alone or with another drug (cemiplimab), in 500 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if the drug can shrink tumors. Because …

This study tests IKS014, a drug designed to seek out and destroy HER2-positive cancer cells, in people with advanced solid tumors like breast, stomach, and gastroesophageal cancers. The main goals are to find the safest dose and check for early signs of tumor shrinkage. About 165…

Researchers are testing whether a single oral chemotherapy drug, capecitabine, can safely replace standard multi-drug chemotherapy in people with low-risk early triple-negative breast cancer after surgery. The trial enrolls adults with small, lymph-node-negative tumors and gives …

This study tests whether giving siltuximab alongside restarting immunotherapy can prevent severe immune-related side effects in people with advanced cancer. About 40 adults who previously had serious side effects from immunotherapy will receive siltuximab to calm the immune syste…

This early-phase trial tests a new drug called RPTR-1-201 in 150 adults with advanced solid tumors that cannot be cured with standard treatments. The drug works by helping the body's immune cells attack cancer. The study aims to find the safest dose and see if the drug shrinks tu…

This study is the first to test AVZO-021, an oral drug that blocks a protein called CDK2, in people with advanced solid tumors. The trial will enroll about 430 adults with certain breast, ovarian, or other cancers. The goal is to find safe doses and see if the drug can shrink tum…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This Phase 2 trial tests a new antibody drug (QL1706) combined with chemotherapy in 40 people with early triple-negative breast cancer. The treatment is tailored based on how the tumor responds after initial cycles, with the goal of avoiding certain heart-damaging drugs if possib…

This Phase II trial tests whether adding neratinib to the standard drug trastuzumab deruxtecan works better than trastuzumab deruxtecan alone for HER2-positive breast cancer that has spread to the brain and cannot be removed by surgery. About 202 women aged 18-70 will be randomly…

This study is testing whether combining a targeted drug (abemaciclib) with precise radiation (stereotactic radiosurgery) can better control brain tumors in people with a common type of breast cancer (HR+/HER2-). About 31 participants will receive both treatments along with hormon…

This phase II trial tests whether taking leucogen alongside standard ribociclib therapy can prevent severe neutropenia (dangerously low white blood cell counts) in women with early-stage hormone-positive breast cancer. About 94 participants will receive the combination and be mon…

This study trains Nigerian radiologists to use tablet-based ultrasound to guide breast biopsies, a method that is more accurate than the blind biopsies or surgical excisions currently used. Nine hundred women with suspicious breast lumps will participate. The goal is to make this…

Researchers in Tanzania are testing whether a portable DNA-reading technology called nanopore sequencing can diagnose invasive breast cancer as accurately as standard lab tests, but faster and at lower cost. The study enrolls 100 patients with suspected breast cancer who are unde…

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

Researchers at Columbia University are testing whether tools built into the electronic health record can increase genetic testing for hereditary breast and ovarian cancer among women with a family history of the disease. The study enrolls women aged 21 to 75 who have no personal …

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

Researchers are testing a PET/CT scan that uses a radioactive tracer called 68Ga-CAIX to detect solid tumors. The tracer binds to CAIX, a protein that many solid tumors produce when oxygen is scarce. The study enrolls about 100 adults with suspected or confirmed solid tumors, inc…

This trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…

Researchers at the Grand Hôpital de Charleroi are validating a molecular test called TST79 that looks for circulating tumor DNA in blood plasma. The study enrolls 15 patients with various cancers, including lung, colorectal, breast, prostate, melanoma, and others, who are undergo…

This study compares two types of breast imaging—molecular breast imaging (MBI) and magnetic resonance imaging (MRI)—to see how well each finds or rules out breast cancer in women at high risk. About 300 women will take part. The goal is to find out if MBI works as well as MRI, wh…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This phase I trial is testing a new radioactive tracer called [18F]FTT, which is used with PET/CT scans to find tumor cells in people with solid tumors, including breast, ovarian, and other cancers. The study will enroll 300 participants and aims to see how well the tracer highli…

This study compares synthetic mammography (a 2D image made from 3D data) to standard digital mammography for detecting breast cancer. Researchers will review medical records from 750 women to see if the synthetic method works as well or better, with the added benefit of lower rad…

This study tests whether molecular breast imaging (MBI) can guide biopsies for breast abnormalities that are hard to see on ultrasound or mammography. About 70 women with a prior MBI finding that turned out to be benign will undergo a new MBI-guided biopsy procedure. The goal is …

Researchers at M.D. Anderson Cancer Center are studying whether a preoperative bioimpedance test can identify women with inflammatory breast cancer who are at risk of developing lymphedema. The trial enrolls 150 women aged 18 and older with newly diagnosed inflammatory breast can…

This study explores whether photoacoustic imaging—a technique that uses light and sound waves—can better detect breast cancer in women with dense breasts, where mammograms often fall short. Researchers will scan up to 400 women, including those with suspicious or confirmed breast…

This early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …

This trial tests a handheld device called the ZedScanner, which measures how breast tissue stores electrical energy—a property that differs between healthy, benign, and cancerous tissue. Around 220 women attending a breast clinic will get an extra, non-invasive scan after routine…

Researchers are testing a radionuclide probe that targets PD-L1, a protein some tumors use to evade the immune system. Adults with solid tumors such as lung, cervical, breast, melanoma, or gastrointestinal cancers receive the probe and then undergo whole-body PET/CT imaging. The …

This study investigates whether offering regular breast ultrasound screening to women aged 65 to 80 can increase the rate of early-stage breast cancer detection compared to routine health check-ups. Over 82,000 women from communities in China will be assigned to either receive st…

Researchers are testing a radioactive tracer called 18F-G1 that binds to granzyme B, a protein released when immune cells attack tumors. Adults with solid tumors or blood cancers who are about to start immunotherapy receive an injection of 18F-G1 and then undergo PET/CT scans. Th…

Researchers are testing whether an artificial intelligence platform can analyze blood, stool, and tissue samples to find tiny traces of cancer left behind after curative treatment. The study enrolls 800 adults with early or locally advanced breast cancer, melanoma, or gastrointes…

Researchers test whether a magnetic tracer called Magtrace can do two jobs at once during breast-conserving surgery: outline the area of breast tissue to remove and help find the sentinel lymph node in the armpit. The study enrolls about 35 patients with breast cancer who need br…

This early-stage trial is testing whether a vaccine targeting the MUC1 protein, combined with hormone therapy, can help prevent ductal carcinoma in situ (DCIS) from becoming invasive breast cancer. Fifty women with ER-positive DCIS will receive either hormone therapy alone or hor…

This study tests whether two types of diabetes medications—SGLT2 inhibitors and DPP-4 inhibitors—can prevent heart damage caused by the chemotherapy drug doxorubicin in women with breast cancer. About 150 Egyptian women will be randomly assigned to receive one of the drugs or sta…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

This study tests whether adding one-on-one support from a Diné peer navigator to a culturally-tailored tablet education program helps more Native American women get mammograms. About 200 women aged 40-74 on the Navajo Nation who haven't had a mammogram in the past year will take …

Researchers are testing whether adding the oral drug neratinib to standard T-DM1 therapy can clear tiny amounts of remaining cancer DNA in people treated for early HER2-positive breast cancer. Participants have already had surgery and standard treatment, but sensitive blood tests…

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

Many people with advanced cancer take opioid pain medicines, which often cause constipation. This trial compares two laxatives, macrogol/electrolytes and magnesium hydroxide, to see which works better at preventing constipation when opioids are started. Adults with advanced cance…

This study tests whether taking low-dose aspirin can lower inflammation and reduce the risk of breast cancer in women who have had a baby within the last 10 years. About 60 women planning a breast biopsy will take aspirin and have blood and tissue samples checked for changes. The…

This study tests whether Reishi mushroom extract can reduce fatigue and joint pain in breast cancer patients taking aromatase inhibitors. About 80 women with moderate to severe fatigue will receive either the mushroom extract or a placebo for 8 weeks. The goal is to see if this n…

This study tests whether special hairstyling methods — like braids, cornrows, or a conditioner-and-water mix — can help scalp cooling caps work better to prevent hair loss during chemotherapy. It focuses on people with curly or kinky hair (types 3 and 4), who have been underrepre…

This trial tests a blended e-health program designed to help women with breast or gynecologic cancer cope with fear of their cancer returning or worsening. The program combines remote group sessions with online modules that teach skills to manage unhelpful thoughts and promote he…

This study tests a virtual group program called Breath-Body-Mind (BBM) that uses slow breathing and gentle movements to help young breast cancer survivors (ages 18-50) cope with psychological distress. Thirty participants will be randomly assigned to either the BBM program or a g…

This study tests whether fucoidan, a supplement from brown seaweed, can prevent or reduce fatigue in people with gastrointestinal or gynecologic cancers who are starting chemotherapy. About 34 participants will receive either fucoidan or a placebo daily for up to 16 weeks. Resear…

Researchers at McMaster University are testing whether a structured exercise and education program helps people with cancer stay physically active during treatment. The trial enrolls 129 adults receiving cancer treatment of any type or stage. Participants join one of three groups…

Researchers are testing whether a nerve block called the serratus posterior superior intercostal plane block can reduce inflammation and improve recovery after breast cancer surgery. The trial enrolls 80 women scheduled for breast cancer surgery under general anesthesia. Half rec…

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…

This study tests a decision aid for breast cancer patients experiencing nerve damage (numbness or tingling) from chemotherapy. The tool provides information about long-term nerve symptoms and helps patients discuss treatment priorities with their doctor. Researchers will enroll 2…

This study tests whether an AI-powered chatbot can help young adult cancer survivors manage ongoing symptoms like fatigue, anxiety, and sleep problems. Participants aged 18-39 who have finished primary cancer treatment will interact with the chatbot to get tailored educational su…

Researchers in China are observing how well the approved medicine HR20013 prevents nausea and vomiting caused by anticancer treatment. The study plans to follow about 3,000 adults with any tumor type who receive HR20013 as part of their usual care at more than 30 hospitals. It wi…

This trial explores whether inhaling essential oils like peppermint, lavender, or ginger can help reduce nausea and anxiety in cancer patients receiving chemotherapy infusions. Current anti-nausea drugs often cause constipation and fatigue, so researchers are looking for gentler …

Researchers are comparing two music-based programs to see which may better reduce anxiety in people with advanced cancer. One program pairs participants with a music therapist who uses an AI-powered platform to write songs together. The other has trained staff guide participants …

This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can reduce anxiety, depression, and existential distress in people with advanced cancer. Two hundred participants will receive either psilocybin or an active…

Researchers at Linkoeping University are co-designing a gamified AI medical yoga app with cancer patients and stakeholders, then testing how feasible and usable it is for home-based rehabilitation. Ten patients undergoing cancer treatment who speak Swedish will use the app for tw…

This study compares two ways to treat breast cancer that has spread to nearby lymph nodes: targeted radiotherapy or surgical removal of the nodes. The goal is to see which approach better preserves arm function and reduces the risk of long-term arm swelling. About 1,060 adults wi…

Researchers are testing a supervised online exercise program called Exercising Together for couples where one partner receives radiation treatment for breast or prostate cancer. The program adds communication and mutual support to standard physical training. The trial measures wh…

This pilot study tests a program called ACCESS, where a community navigator helps Black and Latina women with metastatic breast cancer connect to supportive care and community resources. Participants receive six coaching sessions and monthly check-ins over 16 weeks. The goal is t…

This study is testing a smartphone app called I-STAMP that helps people with advanced cancer keep track of their pain and medications. About 73 participants will use the app and rate how easy it is to use and how helpful it is. The goal is to see if the app can make managing canc…

This study tests whether adapted Argentine Tango dancing can reduce nerve damage symptoms caused by breast cancer chemotherapy. About 140 survivors who completed taxane-based chemo at least 3 months ago will take 16 dance sessions over 8 weeks. Researchers will measure changes in…

This trial tests an educational program called A-PACT for people with solid tumors who are at high risk of decline. Trained lay health workers coach patients on how to discuss their care goals and end-of-life wishes with their medical team. The study will see if this reduces unpl…

Researchers are testing whether combining osteopathy, a hands-on physical therapy, with therapeutic hypnosis eases chronic pain and emotional distress in cancer patients better than osteopathy alone. The trial enrolls 80 adults with cancer who have had pain for at least three mon…

This study tests whether an Enhanced Recovery After Surgery (ERAS) protocol can reduce opioid prescriptions and pain after breast conserving surgery. 260 breast cancer patients will be randomly assigned to receive either the ERAS protocol or standard care. The ERAS protocol inclu…

This trial tests an AI-powered avatar called ELISA that helps cancer patients learn about their treatment. Patients starting a new cancer therapy often struggle to remember complex information. The avatar provides personalized answers based on approved content. The study compares…

This study tests a program called ROCKS that helps people with advanced cancer and their family caregivers build optimism, communication skills, and knowledge to discuss advance care planning. 152 patient-caregiver pairs will be randomly assigned to the ROCKS program or usual car…

This study tests whether a personalized diet can improve quality of life in 100 women with advanced gynecologic or breast cancer who are receiving antibody-drug conjugate therapy. Participants will either follow a diet tailored to their needs or receive general Mediterranean diet…

Researchers are developing and testing MybYte, a smartphone tool that offers personalised nutrition advice to teenagers aged 12 to 18 who are undergoing cancer treatment. In the first phase, about 15 teenagers help refine the tool through interviews and feedback. In the second ph…

Many breast cancer survivors face depression and anxiety long after treatment ends. This trial tests an eight-week online compassion meditation program called Cognitively-Based Compassion Training, delivered by video conference. It compares survivors who take the program with a s…

This study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…

This pilot study tests whether a supervised treadmill walking program can help people with early-stage triple-negative breast cancer who are receiving immunotherapy before surgery. The main goal is to see if patients can stick with the exercise routine. Researchers will also chec…

This study tests whether a low-level laser applied to specific points on the ear can improve sleep in women with breast cancer who have insomnia. Seventy participants will receive either real or sham laser acupuncture twice a week for five weeks. Sleep quality, fatigue, and mood …

Researchers are testing whether adding a specialized radiation technique called spatially fractionated radiation therapy (SFRT) to standard palliative radiation helps people with large, inoperable solid tumors feel better. SFRT delivers high doses of radiation in a grid pattern, …

This study tests a support program for Chinese cancer patients and survivors that includes education sessions, counseling, and peer support. The program is delivered by phone or video call. Researchers want to see if the program is practical and whether it improves quality of lif…

This study tests whether a negative pressure wound therapy (NPWT) device, which uses a vacuum to help wounds heal, works better than standard bandages for the abdominal incision in obese patients having breast reconstruction surgery. About 80 participants will be randomly assigne…

This Phase III trial tests whether American ginseng can reduce fatigue in 160 cancer patients. Fatigue is a common and tough side effect of cancer and its treatment. Participants will take either ginseng or a placebo, and researchers will measure changes in fatigue levels over ti…

This study tests whether a virtual exercise and education program can help breast cancer patients maintain their fitness, heart health, and quality of life while undergoing chemotherapy. About 120 patients with stage I-III breast cancer will be enrolled. Participants will attend …

This study tests whether two types of breathing exercises—pranayama and pursed-lip breathing—can reduce pain, anxiety, and improve vital signs in women after breast surgery. 126 participants will be randomly assigned to one of three groups: pranayama, pursed-lip breathing, or sta…

This study tests a new program called Open Door for Cancer (OD-C) designed to help older adults (65+) who have been diagnosed with breast, colorectal, lung, or prostate cancer and are feeling depressed. The program aims to make it easier for them to start mental health care. Rese…

This pilot study tests a financial psycho-oncology program for cancer patients facing financial hardship. Participants attend six one-hour sessions over three months that combine emotional support with practical financial education. The study aims to see if the program is feasibl…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests a program called Contingency Management that gives Veterans rewards for quitting smoking, verified by breath tests. Researchers will first gather feedback from Veterans and staff, then run a small pilot with 20 Veterans over 5 weeks. If successful, a larger trial…

This study looks at whether a nerve graft during nipple-sparing mastectomy can help restore feeling in the nipple. About 20 women with early-stage breast cancer will be randomly assigned to receive the nerve graft or not. The goal is to see if the procedure improves sensation and…

This study tests whether a guided digital self-hypnosis program can reduce hot flashes in women with breast cancer who are on hormone therapy. Hot flashes are a common side effect that often leads patients to stop treatment, raising the risk of cancer returning. Over three weeks,…

This study tests whether a digital support program can help people with breast, prostate, or colorectal cancer reduce the time they spend sitting during their treatment. The goal is to improve their well-being and lower future health risks. About 172 participants will use an acti…

This study tests if a steroid mouthwash can prevent or reduce mouth sores caused by the cancer drug datopotamab deruxtecan (Dato-DXd). About 100 adults with advanced breast or lung cancer will use the mouthwash and be monitored for 12 weeks. The goal is to see if this simple step…

This study tests whether hyperbaric oxygen therapy—breathing pure oxygen in a pressurized chamber—can reduce nerve pain and numbness caused by the chemotherapy drug nab-paclitaxel in breast cancer patients. About 160 women who have finished chemo and developed nerve symptoms will…

This study tests whether a single 60-minute counseling session can reduce anxiety and depression in breast cancer patients who are waiting for ongoing therapy. About 26 participants will receive the session plus a booklet, and researchers will measure how helpful and practical it…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This study tests whether a home-based exercise and nutrition program, called prehabilitation, can improve physical function in adults aged 65 and older with breast cancer before they have surgery. The program includes strength, balance, and flexibility exercises tailored to each …

This study tests whether a CO2 laser combined with a regenerative gel can relieve vaginal atrophy symptoms—like dryness, pain, and itching—in 180 breast cancer survivors who cannot use hormone therapy. Participants will be randomly assigned to receive the laser plus gel, laser al…

Chemotherapy often causes nausea and vomiting, which is especially hard for children. This study tests a new IV drug called NEPA (fosnetupitant/palonosetron) to prevent these side effects in kids with cancer. The trial has two parts: first, an open-label phase to find the right d…

Researchers are testing whether an AI-based exercise coaching system helps breast cancer survivors exercise more regularly and improve their quality of life. The trial enrolls 60 women who have finished major cancer treatment and are clinically stable. Half receive personalized e…

This study tests whether taking a high dose of whey protein after each workout helps breast cancer survivors gain more muscle and lose more fat compared to exercise alone. Participants are women aged 20 to 89 who have completed treatment for breast cancer and are prescribed exerc…

This study tests whether a dietary supplement called Redsenol-1 Plus can safely reduce fatigue in adults who have had cancer treatment. 72 participants will take either the supplement or a placebo for 12 weeks. The main goal is to see if fatigue levels improve, as measured by a s…

This study provides long-term follow-up for people who previously received gene therapy or other immunotherapy for cancers like prostate, liver, breast, colon, or lung cancer. Participants will have annual health check-ups or phone calls for up to 15 years to monitor for any long…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study looks at how BRCA gene mutations and breast cancer treatments affect the ovaries in premenopausal women. Researchers will measure hormone levels in the blood before, during, and after cancer therapy to understand the risk of early menopause and fertility problems. Abou…

This study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This observational study from Rutgers University aims to learn how genes influence breast cancer risk. Anyone 18 or older living in the US can join, even without a cancer diagnosis. Participants fill out online health surveys and provide a saliva sample by mail. The study will an…

This study is testing a program to help Native American cancer patients get better coordinated care. It brings together a cancer center and tribal health systems to improve communication and support. About 187 adults newly diagnosed with cancer will take part. The goal is to see …

Many women treated for breast cancer report lasting pain and fuzzy thinking after chemotherapy, but researchers have not studied whether the two are connected. This study follows 182 women with non-metastatic, hormone receptor-positive breast cancer from before chemotherapy throu…

This study is collecting blood samples from 170 people with metastatic breast cancer to look for ESR1 gene mutations, which can make cancer resistant to hormone therapy. Researchers will compare these blood-based results with standard tissue tests. The goal is to better understan…

This study tests a fertility preservation decision aid for young cancer survivors and their parents. The goal is to see if the tool helps them better understand fertility status and future parenthood options. About 358 participants will be randomly assigned to receive either the …

This study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their routine care. Researchers will collect blood samples and medical records to see how long the cancer stays controlled with each ADC treatmen…

This study is auditing a surgical technique called Targeted Sentinel Node Biopsy (TSNB) for breast cancer patients who have a small number of cancer cells in their lymph nodes. The goal is to see if this less invasive procedure can accurately identify cancer spread while causing …

This study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …

This study aims to find markers and causes of cancer by analyzing participants' DNA, RNA, and tissue samples. Researchers will use this information to improve cancer prevention, early detection, and treatment. The study will enroll 500 adults with cancer at Mayo Clinic.

This study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

Researchers at the Medical College of Wisconsin run an observational registry for adults who receive care for a cancer-related condition. The registry collects medical data and biospecimens, both from past records and from samples given during the study. The goal is to study how …

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study monitors 1,500 adults with breast cancer who receive LUMISIGHT during lumpectomy surgery. Researchers will track how often serious allergic reactions occur within 60 minutes of injection. No new drug is being tested; the goal is to better understand the safety of this …

Researchers are following 5,000 women and men who carry a BRCA1 or BRCA2 gene mutation to see who develops breast or ovarian cancer over their lifetime. Participants answer questionnaires about their health and cancer history for up to 10 years. The goal is to understand how ofte…

Researchers are collecting blood, tumor and imaging data from 150 adults with locally advanced or metastatic breast cancer to understand why some treatments work and others stop working. The study follows people who receive standard modern therapies such as CDK inhibitors, antibo…

This study looks at how tamoxifen, a common breast cancer drug, affects certain immune cells called neutrophils. It focuses on a process where neutrophils release web-like traps that may cause side effects. Researchers will study blood samples from 290 women with ER+ breast cance…

This study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…

Researchers are tracking 496 women, some with breast cancer and some without, to see whether having an autoimmune thyroid condition affects breast cancer outcomes. Over five years, they will collect blood, stool, and neck lymph node samples to measure thyroid autoantibodies, look…

Researchers are following thousands of people who were treated for early-stage invasive breast cancer in past GEICAM clinical trials. The study collects health information for about 30 years after those original trials ended. The goal is to see how many remain cancer-free, how ma…

This study looks at how breast cancer cells change after a short course of hormone therapy in women with and without a BRCA2 gene mutation. Researchers will measure a protein called Ki67, which indicates how fast cancer cells are growing. The goal is to see if BRCA2 carriers have…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study tests a decision-making tool for women newly diagnosed with early-stage breast cancer who are considering removing the healthy breast as a preventive measure. The tool aims to improve knowledge and reduce uncertainty about the choice. Only 15 participants are enrolled,…

This study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…

This study will review medical records of about 240 adults in Kazakhstan with HER2-positive metastatic breast cancer to see how they were treated and how well they did. Researchers will look at treatments given in routine care (except one specific drug) and track outcomes like ho…

This study is analyzing tumor and blood samples from 10,000 adults with advanced solid tumors or blood cancers to find genetic changes that can be targeted by existing drugs. The goal is to see how often these 'actionable' alterations occur and to guide patients toward personaliz…

This study looks at whether special tests can predict which off-guideline drugs—FDA-approved for other cancers but not for a patient's specific cancer—might work for them. It involves 300 advanced cancer patients whose doctors are willing to try these drugs. The goal is to see ho…

This study looks at people who have a gene variant (called a secondary finding) that was found during genetic testing for another reason. Researchers want to understand how these variants affect health, how people respond to the news, and whether they follow medical advice. Up to…

Researchers are tracking 700 adults with solid tumors who are starting systemic anti-cancer treatment. The study measures body composition with bioimpedance and muscle performance with grip strength and chair-rise tests, plus activity trackers, to see whether sarcopenia predicts …

This study is a registry that collects information from 1867 people with advanced breast cancer that cannot be removed by surgery or has spread. Researchers will track different breast cancer subtypes and patient characteristics to better understand the disease in real-world sett…

This study is investigating whether a patient's body weight changes how the drug Trastuzumab-Deruxtecan (T-DXd) behaves in the body. Researchers will compare drug levels and side effects between normal-weight and overweight or obese patients with advanced breast cancer. The goal …

This study looks at how the location of treatment affects whether people with early-stage HER2-positive breast cancer stick to their therapy plan. Researchers will compare patients who have to travel far for treatment with those who don't. The goal is to see if making treatment m…

This study looks at whether the number of steps breast cancer patients take each day, tracked by a smartwatch, is linked to how well their treatment works. About 82 women with non-metastatic HER2-negative breast cancer will wear a Huawei Fit 2 smartwatch during chemotherapy befor…

This observational study is testing whether a blood test called a liquid biopsy can provide useful information for people with early-stage breast cancer who are about to start treatment before surgery. The test looks for tiny fragments of tumor DNA circulating in the blood. Resea…

This study looks at how the COVID-19 pandemic impacted out-of-pocket costs, lost wages, and unemployment for 600 breast cancer patients undergoing surgery. Participants will fill out questionnaires about their financial experiences. The goal is to understand the financial toxicit…

This trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…

This study follows 2,000 adults with newly diagnosed breast, colorectal, lung, melanoma, or lymphoma cancer who are receiving chemotherapy or immunotherapy. Researchers will track whether using cannabis or cannabinoids helps with symptoms like pain or nausea over time. No treatme…

Researchers are building a large registry of genomic, molecular, and clinical information from people with suspected or confirmed cancer. Participants provide tumor sequencing data and allow the team to follow their treatment and outcomes over time. The goal is to discover gene a…

This study follows 100 people with stage III triple-negative breast cancer to see how standard treatments affect their quality of life. Participants fill out questionnaires about their well-being at nine time points and may give blood samples to track cancer DNA. The goal is to l…

This study looks at whether a special health check-up done over video (telemedicine) can help find weak spots in older adults with cancer and guide their care. It includes 216 people aged 65 and older with cancer who are starting a new treatment. The goal is to see if this approa…

This study will include about 2,748 people with breast, gynecologic, or pancreatic cancer. Researchers want to see if adding patient-reported outcomes—like symptoms, preferences, and travel distance—to tumor board discussions helps doctors make better treatment decisions. The goa…

This study aims to understand why some breast cancers become resistant to therapy. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in cancer cells tha…

This study looks at whether starting with a lower dose of CDK4/6 inhibitor pills (palbociclib or ribociclib) and gradually increasing the dose helps older adults (age 65+) with metastatic breast cancer tolerate side effects better and stay on treatment longer. About 500 participa…

This study is testing a new questionnaire called SOCS-OTS to see if it can correctly identify cancer survivors who need occupational therapy. Researchers at MD Anderson will compare it to a standard screening tool in 80 adults. The goal is to make sure the new tool accurately fin…

This study creates a registry for people with inflammatory breast cancer, a rare and aggressive form of the disease. Researchers will collect blood, tissue, and stool samples along with medical information from up to 1,200 participants. The goal is to build a resource for future …

This study is looking for early signs of heart and lung damage in people receiving radiation for chest cancers. Researchers will use PET/MR scans and blood tests before and after treatment to see if they can predict who will develop problems like pulmonary hypertension. The goal …

This study aims to understand why some cancer patients develop autoimmune side effects when treated with immune checkpoint inhibitors. Researchers will analyze blood cells and genetics from 600 participants to identify features linked to these side effects. The goal is to improve…

This study aims to create and improve educational materials about genetic testing for cancer patients from diverse backgrounds. Researchers will interview 445 people with breast, ovarian, pancreatic, prostate, or colorectal cancer who speak English, Spanish, or Haitian Creole. Th…

This study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…

This study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

Researchers in Bogota, Colombia, are reviewing the medical records of 370 women treated for breast cancer between 2014 and 2024. They want to see how different molecular subtypes of the disease relate to survival, recurrence, treatment response, and side effects. The study also l…

Researchers at Tan Tock Seng Hospital are building a shared dataset to understand what makes some older adults become frail after a stroke, brain injury, knee arthritis or breast cancer. The study follows 500 Asian adults aged 50 and older who live in the community, measuring bod…

This study will follow 81 people with early-stage, hormone-positive breast cancer who are at high risk of the cancer coming back. Researchers want to see how often patients take their prescribed CDK4/6 inhibitor pills (abemaciclib or ribociclib) alongside standard hormone therapy…

This study explores the link between physical activity and thinking skills in people who survived cancer as adolescents or young adults. Researchers will use computer-based brain games to measure memory and attention. The goal is to understand how exercise might help brain health…

This pilot study looks at how different resistance training routines change levels of myokines—molecules released by muscles during exercise—in women who have finished breast cancer treatment. Participants will be assigned to one of three exercise regimens (conditioning, strength…

Researchers are collecting weekly urine samples from adults with solid tumor cancers to look for metabolic changes that occur as death approaches. The study aims to understand the biology of dying and explore whether a test could one day predict the last days or weeks of life. Be…

This study looks at how sleep disturbances impact thinking skills and quality of life in 75 women treated for breast cancer. Participants will undergo brain scans, sleep tracking, and cognitive tests over six months. The goal is to understand the links between sleep, brain functi…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study will follow 6,000 children, adolescents, and young adults with cancer in low- and middle-income countries. Researchers will collect data from medical records and questionnaires to understand why treatment failure and severe side effects are more common in these setting…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study looks at whether radiation therapy for breast cancer affects the thymus, a small gland in the upper chest that helps produce immune cells. Researchers will collect blood samples from young women aged 18 to 50 who are receiving radiation after breast cancer surgery, as …

This study is collecting information from up to 40,000 cancer patients who are receiving radiation therapy. Researchers will track their outcomes to better understand what works and how to reduce side effects. The goal is to improve patient care by learning from real-world treatm…

This early-stage trial is testing whether cannabidiol (CBD), a compound from cannabis, can affect breast cancer cell growth. Up to 84 women with invasive breast cancer will take either a low or high dose of CBD or a placebo for 5 to 56 days before their surgery. Researchers will …

Researchers are following 1,700 women aged 60 and older who were diagnosed with early-stage breast cancer to see how their thinking and memory change over time. The study measures attention, processing speed, learning, and memory using standard neuropsychological tests, and check…

This study watches how the lymphatic system changes after radiation therapy in 40 women with breast cancer. Researchers use a safe dye and special camera to see early signs of arm swelling (lymphedema). The goal is to find ways to predict and prevent this side effect in the futur…

This study looks at how gut bacteria affect diarrhea and other stomach issues in people with HR+/HER2- breast cancer taking the drug abemaciclib. In the first part, researchers will collect stool samples to track bacteria changes. In the second part, a small group will try eating…